Clinical considerations for the development of biosimilars in oncology

Despite availability of biologic therapies, limited patient access to many of the most-effective cancer treatments affects overall health outcomes. To address this issue, many governments have enacted legislation for the approval of biosimilars. The term “biosimilar” refers to a biologic product tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Socinski, Mark A, Curigliano, Giuseppe, Jacobs, Ira, Gumbiner, Barry, MacDonald, Judith, Thomas, Dolca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623533/
https://www.ncbi.nlm.nih.gov/pubmed/25621390
http://dx.doi.org/10.1080/19420862.2015.1008346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623533/
https://www.ncbi.nlm.nih.gov/pubmed/25621390
http://dx.doi.org/10.1080/19420862.2015.1008346

Ejemplares similares